Abstract Adherent natural killer (A-NK) cells were isolated from splenic lymphocytes and treated with long-
Introduction
Adoptive immunotherapy using lymphokine-activated killer (LAK) cells or plastic-adherent natural killer (A-NK) cells [3] , in combination with recombinant interleukin-2 (rIL-2), has proved to be useful in a variety of animal tumor models and in some cancer patients. The eects are usually transient and require the transfer of large numbers of LAK cells and a high dose of rIL-2 [21, 22] . The majority of patients treated, however, have not shown any de®nite response to such therapy [21, 33] . It is in general believed that, when transferred intravenously, LAK cells migrate selectively into tumor tissues and exert their antitumor eects though direct cellular attachment or ®rm adhesion to tumor cells.
Lymphocyte migration into the perivascular region occurs through the mechanism of lymphocyte homing though vessels resembling high-epithelium venules (HEV) during the course of a chronic in¯ammatory reaction [24, 25] . The ®rst step in the migration of LAK cells into tumor tissue is the process of LAK cell adherence to the vascular endothelium. A number of studies have demonstrated that various kinds of adhesion molecule mediate the adherence of lymphocytes to the endothelium and the extravasation [24, 25] . The transmigration of NK cells though endothelial cells has been shown to be dependent on lymphocyte-functionassociated antigen 1 (LFA-1) [5] , and the vascular antigen VLA-4 mediates NK cell adhesion to the extracellular matrix component ®bronectin [10] . The migration capacity of NK cells is found to be higher than that of other lymphocytes. NK cells also have the ability to increase the migratory response rapidly [23] . Localization of A-NK cells in the microvasculature of growing tumors results from recognition of the intracellular and vascular cell-adhesion molecules ICAM-1 and VCAM-1 on the tumor endothelium, mediated by LFA-1 and vascular lymphocyte-function-associated protein VLA-1 [16] . It has therefore been hypothesized that the formation of HEV-like vessels in the peritumoral region prior the adoptive transfer of antitumor A-NK cells might be crucial for selective accumulation or in®ltration of the eector cells into tumor tissue through the lymphocyte homing mechanism. Deeper insight into the selective accumulation of antitumor LAK cells transferred to tumor-bearing animal models may guide therapeutic approaches in further clinical trials.
Thus, in the present study, we attempted to clarify what kind of antigenic phenotypes or adhesion molecules and cytotoxic killer activity against tumor cells A-NK cells can express, when cultured for a long period in vitro. Furthermore, we tried experimentally to demonstrate what kind of experimental protocol is useful for the selective accumulation of A-NK cells in mammary tumor tissues, induced by a chemical carcinogen in rats, and for the eective suppression of tumor growth, when various kinds of adjuvant were injected into the peritumoral region. The data obtained indicate that peritumoral injection of some kinds of adjuvant prior to the adoptive cell transfer therapy can augment the accumulation of eector cells into the tumor tissue as well as the extent of tumor regression. The mechanisms by which the eector cells accumulate in the tumor tissue and exert antitumor eects are discussed.
Materials and methods

Animals
Speci®c-pathogen-free female DA/Slc rats, 8±10 weeks old and weighing 100±120 g, were purchased from Japan Slc Co.(Hamamatsu, Japan) and maintained in a speci®c-pathogen-free animal facility at the Hamamatsu University School of Medicine. The rats were used throughout the study.
Culture medium and interleukin-2
The culture medium consisted of RPMI-1640 medium (Nissui Co., Tokyo, Japan) supplemented with 10% fetal calf serum (FCS; Nichirei Co., Tokyo, Japan), 100 units/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. Human rIL-2 was kindly provided by Shionogi Co. (Osaka, Japan).
Preparation of A-NK cells
The preparation of A-NK cells has been described elsewhere [11, 31] . Brie¯y, single-cell suspensions from DA rat spleen were prepared in RPMI-1640 medium and the splenic lymphocytes were isolated by Ficoll-Paque (density = 1.077 g cm )3 ; Pharmacia, N.J., USA) four-step Percoll gradients (48%, 52%, 56% and 60% Percoll). The gradients were centrifuged at 400 g for 30 min and the cells were collected from the 48%/52% interface [20] . After two washes, 10´10 6 cells were transferred into 25-cm 2 plastic asks (Falcon Co., N.J., USA) with 5 ml complete medium and 2000 U/ml rIL-2. After 2±3 days of incubation at 37°C 5% CO 2 in air, non-adherent spleen cells were removed, and the¯asks were gently washed with preheated (37°C) complete medium to remove cells not attached to the plastic. A 5-ml portion of fresh complete medium containing 1000 U/ml rIL-2 was added and the cells were cultured in vitro for more than 50 passages (approximately 150 days). The A-NK cells were harvested by scraping the¯asks with a rubber policeman 0, 8, 30 and 150 days after incubation.
Antibodies
Three dierent monoclonal antibodies (mAb), Mar1, Mar2 and Mar3, recognizing rat macrophages, were produced in our laboratory [36] . The mouse mAb 1F4 (anti-CD3), W3/25 (anti-CD4), OX6 (anti-Ia), OX8 (anti-CD8), OX39 (anti-IL-2 receptor), AG-1 (anti-asialoGM-1) anti-(hamster Ig) second antibody and a¯uo-rescein-isothiocyanate-conjugated rabbit F(ab¢) 2 fragment anti-(mouse IgG) were purchased from Seikagaku Co. (Tokyo, Japan). Anti-(adhesion molecule) mAb WT-1 (anti-LFA-1a), WT-3 (anti-LFA-1b), 1A29 (anti-ICAM-1), and HRL4 (anti-LECAM-1) were kindly provided by Dr. M. Miyasaka (Osaka University School of Medicine, Osaka, Japan). A second antibody, alkaline-phosphatase-conjugated anti-(mouse IgG), was purchased from Sigma Chemical Co. (Mo. USA).
Immunohistochemical staining
Cell smears were prepared by cytospin centrifugation (Shandon Ltd., Cheshire, UK). The un®xed tumor specimens were embedded in OCT (Miles Inc., Ind., USA) and frozen at )70°C, and 5-lm cryostat sections were prepared. Tissues were stained by an indirect immunoalkaline phosphatase method and the Fast red technique [2, 17] . The slides were incubated with the primary antibodies for 60 min at room temperature. After washing with 0.01 M cold phosphate-buered saline (PBS) pH 7.4, the slides were incubated with second antibodies for 45 min at room temperature. The slides were developed, after additional washes with PBS, using ABC alkaline phosphatase substrate kit 1 (Vector red; Funakoshi Co., Tokyo, Japan). Finally, the slides were slightly counterstained with hemotoxylin solution and observed by a light microscope.
Flow-cytometric analysis
A-NK cells (1´10 6 ) were treated with mAb for 30 min at 4°C. After two washes with PBS, the¯uorescein-isothiocyanate-conjugated rabbit anti-(mouse IgG) antibody at 1:50 dilution was added and incubated for a further 30 min at 4°C. After two washes with PBS, the cells were analyzed on an EPICS Pro®le¯ow cytometer (Colt Co., Fla., USA).
Preparation of mammary-tumor-bearing rats
Female DA rats received an intravenous injection of a fat emulsion containing 0.5% 7,12-dimethylbenzanthracene (DMBA; Upjohn Co., Mich., USA) [15] . Between 50 and 80 days after DMBA administration, when the palpable tumors had reached about 10 mm in diameter, the tumors were removed and washed twice with cold RPMI-1640 medium. Small fragments (about 2´2 mm) of the freshly removed tumor were inoculated subcutaneously into the axillary region of syngeneic DA hosts. Within 2±3 weeks after the grafting, the tumor was well developed and had reached about 8±10 mm in diameter when it was used to study the in vivo treatment of mammary-tumor-bearing rats with A-NK cells.
Primary culture of DMBA-induced mammary tumor cells DMBA-induced mammary tumor cells were incubated as described by Ethier [8] .
In vitro cytotoxicity assay Cytotoxicity was measured in a standard 4-h 51 Cr-release microcytotoxicity assay using 96-well V-bottomed microplates (Falcon Co., N.J., USA). As the target cells, YAC-1 and P815 cells, obtained from the Cancer Cell Repository of Tohoku University (Sendai, Japan), and primary cultured mammary tumor cells were used. Each sample of 10 6 target cells was labeled with 100 lCi Na 2 51 CrO 4 (Amersham Co., Buckinghamshire, England), washed and seeded into triplicate wells to give various E/T ratios in ®nal volume of 200 ml. After incubation at 37°C for 4 h, 100 ml supernatant was removed from each well and counted in a gamma counter (Aloka Co., Tokyo, Japan) to determine the experimental release (ER). The spontaneous release (SR) was obtained from wells that contained target cells and medium only, and the total release (TR) was obtained from wells receiving 1% Triton X-100 solution. The percentage cytotoxicity was calculated as: cytotox- H] uridine (Amersham Co., Buckinghamshire, England) at 37°C. After three washes, the cells were resuspended in RPMI-1640 medium at a concentration of 30´10 6 /ml. Labeled A-NK cells were administered to the female DA rats by intravenous injection [35] . The cell viability was over 90%. Recipient rats were injected intraperitoneally with 50 000 units rIL-2 2 h earlier and treated with two subsequent doses of rIL-2 separated by an 8-h interval. The abdominal aorta was¯ushed with 50 ml 0.9% saline solution 3, 12, 24, 48 and 72 h after injection, to minimize the background radioactivity. Various organs were then removed and weighed. The distribution of A-NK cells in each organ was evaluated by measuring the radioactivity with a sample oxidizer (Aloka Co., Tokyo, Japan) and by autoradiography. Aliquots of tissue samples from these organs were oxidized in a sample oxidizer, and the end-product ([ 3 H] water) was determined in a liquid scintillation counter (Beckman Co., Cal., USA). The radioactivity recovered in each experiment was expressed as cpm/mg wet tissue. Paran-embedded tissues for autoradiography were cut at 5 lm, and deparanized slides were dipped in autoradiographic emulsion (Konika Co., Tokyo, Japan). After exposure for 2 weeks at 4°C the slides were developed, ®xed and stained with hematoxylin.
In vivo treatment studies
The antitumor eect of the combination of peritumoral injection of adjuvant and A-NK cell adoptive transfer was studied in vivo, by determining the tumor size and the survival time of mammarytumor-bearing rats after the in vivo treatment. Mammary-tumorbearing rats were divided into six groups (n = 6), as described before: the control, FCA, FIA, BCG, FCA + BCG, and FIA + BCG groups. Ten days after the peritumoral injection of various kinds of adjuvant, 30´10 6 A-NK cells were administered in combination with multiple injections of rIL-2. To determine the blocking eect of anti ICAM-1 mAb on the ability of the combination of adjuvant and A-NK cells to suppress the growth of mammary tumors, 30´10 6 A-NK cells and anti-ICAM-1 mAb (1A29, 0.1 mg/kg body weight) were injected intravenously into the mammary-tumor-bearing rats that had received the peritumoral injection of various of adjuvants 10 days previously. The recipient rats in each group were injected intraperitoneally with 50 000 units rIL-2 2 h prior to the injection of A-NK cells and treated with two subsequent doses of rIL-2 with separated by an 8-h interval on 4 consecutive days. Tumor size was measured with a caliper every 5 days for 30 days.
Statistical analysis
Statistical analysis was performed using the two-tailed Student's t-test.
Results
Characteristics of A-NK cells after long-term culture
Expression of the surface marker phenotypes of A-NK cells was analyzed on an EPICS¯ow cytometer to quantify the degree of cell staining (Fig. 1) 
Cytolytic activity against tumor cells
Because there were some dierences in the intensity of surface marker expression among early-, middle-, and late-stage A-NK cells, it is pertinent to examine the relationship between the expression of these molecules and the in vitro cytolytic activity against tumor cells. The cytolytic activity of A-NK cells against fresh mammary tumor cells, YAC-1, and P815 targets was assessed with a 51 Cr-release microcytotoxicity assay. A-NK cells obtained after 8, 30, and 150 days of culture showed signi®cant cytolytic activity against all targets, compared with normal spleen cells (Fig. 2) . Among three kinds of eectors, day-8 A-NK cells showed twice the cytolytic activity of day-150 A-NK cells at various E/T ratios. Day-30 A-NK cells showed a degree of activity intermediate between that of day-8 and that of day-150 cells. More potent cytolytic activity at a low E/T ratio was observed for all eector cells tested than for fresh mammary tumor cells and P-815 cells, when YAC-1 lymphoma cells were used as the targets.
Distribution of A-NK cells in vivo [
3 H]uridine-labeled A-NK cells after 8, 30, and 150 days culture were injected intravenously into normal DA rats or tumor-bearing DA rats, as described previously [4, 32, 35] . Figure 3 shows the distribution pattern of 3 H-labeled A-NK cells in various kinds of organ 3±72 h after a single intravenous injection. Immediately after injection (3 h), a high level of radioactivity (over 60% of the total) was found in the lungs, and 5%±10% of the radioactivity recovered was found in the liver and the spleen. However, autoradiographic observation revealed that most of the 3 H-labeled A-NK cells found in the lungs was adhering to the endothelia of small blood vessels, remaining within the vascular cavity without extravasating into the parenchyma (Fig. 4) .
The radioactivity in the lungs was sharply decreased to 17% of the 3-h radioactivity 12 h after injection, implying the detachment of [ 3 H] A-NK cells from the pulmonary blood vessels. On the other hand, relatively high radioactivity was observed in the spleen (Fig. 3) , whereas very low radioactivity was found in the kidney, the adrenal gland, the small intestine, the thymus and serum (data not shown). Between 24 and 72 h after injection, the radioactivity in all organs tested gradually decreased. No dierence was observed in the distribution pattern among [ (Fig. 6) . It was also observed histologically that the degree of tumor necrosis in the former was much higher than that of the latter.
The formation of HEV-like vessels that permit the extravasation or the in®ltration of lymphocytes into the peritumoral region was investigated histologically. Figure 7 shows a representative collection of HEV-like vessels produced by the prior injection of FCA + BCG into the peritumoral region. Moreover, the in®ltration of mononuclear cells consisting of lymphocytes, natural killer cells, and macrophages was often observed in the perivenular space of HEV-like vessels that were produced within the loose connective tissue of the peritumoral region and the peripheral region of necrotic foci of the tumor tissue.
Expression of adhesion molecules on the mammary tumor cells and on the tumor-in®ltrating lymphocytes + mammary tumor cells in the tumor tissues given the peritumoral injection of FCA + BCG was much higher than that of the saline controls, indicating that the adjuvant injection augments the expression of ICAM-1 molecules on the tumor cells (Fig. 8) . Moreover, it was found that the injection of adjuvant results in the selective accumulation of LFA-1 + lymphocytes into the stroma surrounding the tumor foci.
In vivo treatment studies Figure 9 shows the changes in the growth of mammary tumor tissue from rats receiving various adjuvants by peritumoral injection after adoptive transfer of A-NK cells and rIL-2 treatment. Fifteen days after the tumor grafting, mammary-tumor-bearing rats were given single peritumoral injections of various kinds of adjuvant and then, 10 days later, an intravenous injection of A-NK cells obtained from a 150-day culture. Prior injection of adjuvants resulted in signi®cantly less tumor growth in all the groups tested, compared with that of the control group. A marked reduction was observed particularly in the FCA + BCG and FIA + BCG groups, when evaluated 30±50 days after tumor grafting. In the blocking experiment, simultaneous injection of anti-ICAM-1 mAb (1A29. 0.1 mg/kg) blocked or eectively cancelled the suppressive eect on tumor growth of previously injected adjuvant combined with A-NK cell adoptive transfer (Fig. 10) . No eect was found in the groups treated simultaneously with adjuvants and adoptive A-NK cell transfer (Fig. 11) . The longest mean survival times that were found in the groups pre-treated with FCA + BCG or with FIA + BCG were 48.6 and 45.9 days (P < 0.05) respectively. The survival rate of the two groups was signi®cant higher than that of the control group (Table 1) .
These ®ndings indicate that the peritumoral injection of proper adjuvants augments the in®ltration of eector cells and the cellular interaction with or adhesion to target tumor cells, not only by inducing the neovasculogenesis of HEV-like vessels, but also by augmenting the expression of relevant adhesion molecules on both target tumor cells and eector cells.
Discussion
The eect of adoptive immunotherapy by transfer of LAK cells, which is a novel cancer therapeutic modality, is still controversial and there are many diculties in obtaining a large amount of eector cells and in generating sucient quantities of potent eector cells to exert a broad spectrum of antitumor activity. In the present study, we successfully isolated A-NK cells more potent than standard LAK cells by incubating spleen cells from DA/Slc rats in the presence of rIL-2 for over 150 days. It was revealed that, when incubated in the presence of rIL-2, A-NK cells rapidly change both the surface structure and the expression of their antigenic phenotype, enabling them to adhere to plastic¯asks and exert tumor cytotoxicity. The evidence is follows: (a) the cells showed the morphological characteristics of large granular lymphocytes (data not shown), (b) the cells expressed similar surface markers to NK cells and some adhesion molecules, and (c) the cells acquiring NK cytolytic activity in response to rIL-2 exerted high levels of cytolytic activity against fresh tumor cells, YAC-1 and P-815. These observations are consistent with previous reports of work on rats, humans and mice, in which precursor activity was found to be contained in the LGL/NK lymphocyte subset [29, 30] . After a 150-day incubation, the cytolytic activity of A-NK cells was still signi®cantly higher than that of normal splenic lymphocytes (Fig. 2) . It has been reported that CD8 and asialoGM1 are NK cell markers, that NK cells exhibit major-histocompatibility-complex-unrestricted cytolytic activity against NK-sensitive targets [38] , and that the interaction of rIL-2 with the rIL-2 receptor on NK cells promotes the generation of LAK cells [28] , which thus acquire the ability to recognize and lyse NK-insensitive targets [18] . In the present study, it was also found that some populations of A-NK cells obtained from 8-to 30-day cultures expressed CD8, asialoGM-1, Ia and IL-2 receptor on their surface, indicating that they had acquired the surface markers essential for cytolytic activity against both NK-sensitive and -nonsensitive targets during incubation. It could be assumed that the longer the adoptively transferred cells circulate in a viable and healthy condition in the vascular system, the better are the chances of tumor in®ltration and killing. The continuous supplementing of rIL-2 was essential for the maintenance of cytolytic A-NK cells, because more than 80% of the cells died during the following 24 h, when rIL-2 was removed from an A-NK cell culture plate. Thus, survival, cytolytic activity and tumor localization of A-NK cells depend strictly on the presence of an optimal dose of rIL-2. A-NK cells strongly expressed LFA-1a and LFA-1b molecules on their surface throughout the incubation, although these did the gradually decrease (Fig. 1) . The LFA-1 molecule is likely to play a crucial role in NK cell function, since it was responsible not only for the cellular adhesion of NK cell to potential target cells, but also for transduction of the signal triggering the cytolytic machinery [19, 26] .
In this context, one may speculate that the expression of the LFA-1 molecule on A-NK cells may represent a major pathway for the activation of A-NK cells. Moreover, the expression of ICAM-1 on target tumor cells appears to be an important factor for the accumulation of eector cells in tumor tissue, since previous studies have shown that the cellular interaction between ICAM-1 and its ligand LFA-1 is essential for the function of eector lymphocytes and NK cells, including tumor cell lysis [14, 24, 26] . It is generally assumed that A-NK cells can migrate into lymphoid tissues and into in¯ammatory sites through HEV, indicating that the signals and steps for A-NK cells migration are similar to those of normal lymphocyte recirculation at the molecular level [24±27]. Extravasation of A-NK cell through HEV is regulated by at least three distinct molecular signals; ®rst, tethering to the vessel wall and rolling; second, adhesion strengthening and, third transendothelial migration [25, 26] . Our previous studies on the in vivo localization of A-NK cells in rats supported these observations, as described previously [4, 32] . As shown in Fig. 3, [ 3 H]uridine-labeled A-NK cells were ®rst trapped in the lungs, and subsequently migrated into the liver and the spleen 24 h after injection. The radioactivity in the liver was still higher than that in other organs after 72 h. The autoradiographic observation of the lungs failed to detect signi®cant numbers of A-NK cells in the lung parenchyma, indicating that the A-NK cells adhere to the vascular endothelium and remain within the cavity of the pulmonary capillaries before entering the general circulation 24 h after injection. The present ®ndings indicated that, when , and 150 days of culture, when injected into normal rats and mammary-tumor-bearing DA rats (data not shown). When incubated in the presence of rIL-2, the A-NK cells rapidly changed their expression of antigenic phenotype, but the changes in LFA-1a and LFA-1b were not marked. It has been suggested that LFA-1 plays an important role in A-NK cell migration and this supports previous observations in vitro [5, 16] . The same study showed that LFA-1 expression of A-NK cells was less clearly correlated to A-NK cell binding to and lysis of tumor target cells and their migration into the intercellular space of tumors [7] . Direct migration of A-NK cells from the blood stream to the tumor tissues is initiated by their selective binding to specialized endothelial cells [37] , particularly to HEVlike vessels newly produced within the tumor tissues [34] . Tumor-in®ltrating LAK cells as well as in¯ammatory cells are thought to circulate in the vascular system until they reach their target tissues [3] . A number of granulomatous foci that contain a number of in¯ammatory cells, necrotic foci of tumor tissues and HEV-like vessels were observed in the peripheral region of tumor tissues injected peritumorally with adjuvants, particularly the FCA + BCG mixture (Fig. 7) . In vivo treatment studies used day-150 A-NK cells. Although earlier A-NK cells express higher levels of LFA-1 and are more cytolytic, it is dicult to get enough cells for treatment studies. Peritumoral injection of adjuvants 10 days previously caused marked retardation of tumor growth as compared with the control group, especially in the groups receiving FCA + BCG and FIA + BCG (Fig. 9) . In the ICAM-1 blocking experiment (Fig. 10) , no signi®cant retardation of tumor growth was observed. Moreover, marked accumulation of LFA-1 + lymphocytes in the perivenular space of newly formed HEV-like vessels and in the surrounding stroma of foci of ICAM-1 + tumor cells was observed (Fig. 8) . Once in the tumor area, interactions between adhesion molecules on eector cells and ligand ICAM-1 on tumor cells should result in the ®rm adhesion of each passing eector cell, and chemoattractive factors should provide strong signals that further accelerate the migration of cells across the endothelial lining and into the tumor.
The exact mechanism by which adjuvant injection augments the accumulation of A-NK cells in tumor tissues is poorly understood. Jackson et al. [12] have previously proposed an intriguing hypothesis for the mechanism of action of BCG when it is a major component of FCA. They emphasized the importance of cytokines including interferon c and tumor necrosis factor a released after BCG treatment, which promote the expression of ICAM-1 on tumor cells. Moreover, it was reported that the expression of ICAM-1 on tumor cells is up-regulated by interferon c and tumor necrosis factor a released after intravesical BCG treatment, and that ICAM-1 plays a role in the binding of LAK cells to bladder carcinoma cells, neovasculogenesis of HEV-like vessels, local release of cytokines and cellular interactions [6, 9] . Allavena et al. [1] and Kasahara et al. [13] have shown that LGL themselves possess the ability to secrete a variety of cytokines, including interferon c, IL-1, IL-2, B cell growth factor, and colony-stimulating factor. There is a possibility that the LGL population may play an important immunoregulatory role by inducing self-regulation of cytolytic activity. Moreover, besides the functions of tumor-speci®c killer T cells, other types of nonspeci®c eector, including A-NK cells and macrophages, may play a crucial role in resistance against tumor growth, by in®ltrating eectively into the peritumoral region via adhesion and migration mechanisms between eector cells and the target.
It is clear that adjuvant treatment should be further investigated, including its eects on modulation of cell trac, expression of adhesion molecules, the cytokine network and HEV formation, or its synergism with an immunopotentiator. A number of factors important for the localization of adoptively transferred A-NK cells in a tumor remain to be resolved; for example, (a) the dierence in the activities of subpopulations of eector cells, (b) the dierence in the expression of the antigenic phenotype and adhesion molecules betweeǹ`y oung'' and``old'' A-NK cells during long-term culture, (c) the dierence in the route of administration of A-NK cells, (d) the dierent doses of IL-2 administered, (e) the subsequent release of cytokines in vivo, and the eect of combination, or synergistic eects, with several kinds of immunopotentiator. These questions should be clari®ed to establish a much improved modality for adoptive immunotherapy using A-NK cells. We have demonstrated, using an in vivo model, that long-term cultured A-NK cells indeed possess the ability to in®ltrate selectively into malignant tissues through ICAM-1/LFA-1 interaction on both HEV-like vessels and tumor cells, and that they exert a suppressive eect on tumor growth in when there has been a prior injection of proper adjuvants. It is, however, still an open question whether these rodent models re¯ect the tissue distribution and tumor cytotoxicity of A-NK cells in humans.
